DiaCarta is a translational genomics and precision molecular diagnostics company established in 2011. The company's mission is to improve the precision medicine and molecular diagnostics landscape with highly sensitive and specific technologies that will help patients' lives across the world and impact healthcare treatment plans for the better. The company's fast, accurate, and sophisticated technology has applications across various diseases, according to officials.

"At DiaCarta, we believe in delivering effective technologies and tests to our customers," says Wei Liu, Ph.D., MBA, who is Senior Director for Product Management and Marketing. "We are a patient-centric company working tirelessly to bring specific and sensitive tests to the market that will be essential for a patient's treatment plan. Companion diagnostics help personalize treatments for chronic diseases like cancer that are ever-changing and need a customized approach for treatment. Our tests will help physicians decode the disease foundation and help diagnose each patient with specialized therapy."
 
Since the onset of the Covid-19 pandemic in early 2020, DiaCarta has primarily focused on developing a portfolio of Covid-19 test products. DiaCarter was one of the first companies to receive Emergency Use Authorization from the FDA for a Covid-19 test. Its Covid-19 RT-qPCR test is "the gold standard test for Covid-19 detection owing to its high sensitivity," according to Liu. Additionally, the company has developed three more  Covid-19 tests: a rapid antigen test for at-home testing submitted for FDA EUA approval; an antibody test for research-use only; and a variant test, for research-use only, that can distinguish between Covid-19 variants, including Delta, Omicron, and others. A variant test is essential for monitoring the dominance of a particular variant in a community, notes Liu.

"With this pandemic, we have learned the importance of pandemic preparedness," says Liu. "DiaCarta's proprietary technology platforms allow the company to focus on multiple infectious diseases. This is crucial should we ever face another pandemic."
 
In 2021, DiaCarta relocated its US operations to Hacienda. "The biotech environment in Hacienda is extremely rich with talent and the ecosystem is prime for collaborations," notes Liu. "The presence of large global diagnostic pioneers like Roche and Abbott validates that our choice to move locations has been the right one. We want to be at the center of growth and innovation, for which the Hacienda business center is perfectly suited."

DiaCarta's 40,000 square feet in Pleasanton houses 50 full-time and 20 part-time employees working in the executive offices of the leadership team, the Clinical Laboratory Improvement Amendments (CLIA)-certified lab for testing services, and the  state-of-the-art manufacturing facility for accelerated development and Good Manufacturing Practice (GMP) production of DiaCarta's oncology and Covid-19 test kits. 

"Every day our CLIA- certified lab in Pleasanton continues to provide laboratory RT-qPCR testing services for various businesses and health organizations," he says. "We welcome employees and residents to walk into our facilities for a free Covid-19 test with proof of insurance." 

In addition to its US headquarters at Hacienda, DiaCarta also has more than 70,000-square-feet of facilities in China, which include research and development labs,  R&D labs, GMP manufacturing, and a clinical testing facility. It also has offices in Ireland, Italy, and the United Kingdom. 
 
For more information about DiaCarta, please visit www.diacarta.com or follow @DiaCarta_DX on Twitter.